<DOC>
	<DOCNO>NCT01757691</DOCNO>
	<brief_summary>To evaluate efficacy safety fingolimod 0.5mg versus placebo patient suspect acute demyelinate optic neuritis ( ADON ) receive standard steroid treatment</brief_summary>
	<brief_title>Fingolimod ( FTY720 ) Acute Demyelinating Optic Neuritis ( ADON )</brief_title>
	<detailed_description />
	<mesh_term>Optic Neuritis</mesh_term>
	<mesh_term>Neuritis</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>Clinical sign symptom ADON one eye ( loss vision , pain movement , impairment color vision ) First episode ADON Able undergo treatment IV steroid History unexplained eye neurological symptom last longer 48 hour Optic neuritis eye Concomitant condition either eye , optic neuritis History heart condition/disease Patients uncontrolled diabetes mellitus Patients liver conditions/disease Inability undergo MRI Pregnant nursing woman Women childbearing potential use highly effective method birth control Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Acute demyelinate optic neuritis</keyword>
	<keyword>Optic neuritis</keyword>
</DOC>